KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBT (2016 - 2026)

Emergent BioSolutions has reported EBT over the past 16 years, most recently at $13.4 million for Q1 2026.

  • For Q1 2026, EBT fell 85.54% year-over-year to $13.4 million; the TTM value through Mar 2026 reached $3.5 million, up 105.62%, while the annual FY2025 figure was $82.8 million, 157.94% up from the prior year.
  • EBT for Q1 2026 was $13.4 million at Emergent BioSolutions, up from -$50.7 million in the prior quarter.
  • Over five years, EBT peaked at $142.4 million in Q3 2024 and troughed at -$269.8 million in Q2 2024.
  • A 5-year average of -$58.4 million and a median of -$50.7 million in 2025 define the central range for EBT.
  • Biggest five-year swings in EBT: tumbled 4126.32% in 2023 and later surged 666.12% in 2025.
  • Year by year, EBT stood at -$61.4 million in 2022, then grew by 11.24% to -$54.5 million in 2023, then skyrocketed by 49.36% to -$27.6 million in 2024, then crashed by 83.7% to -$50.7 million in 2025, then surged by 126.43% to $13.4 million in 2026.
  • Business Quant data shows EBT for EBS at $13.4 million in Q1 2026, -$50.7 million in Q4 2025, and $57.6 million in Q3 2025.